Search

Your search keyword '"Kawaoka, Yoshihiro"' showing total 3,319 results
Start Over Author "Kawaoka, Yoshihiro"
3,319 results on '"Kawaoka, Yoshihiro"'

1. Pathogenicity and transmissibility of bovine H5N1 influenza virus

Author

Eisfeld, Amie J., Biswas, Asim, Guan, Lizheng, Gu, Chunyang, Maemura, Tadashi, Trifkovic, Sanja, Wang, Tong, Babujee, Lavanya, Dahn, Randall, Halfmann, Peter J., Barnhardt, Tera, Neumann, Gabriele, Suzuki, Yasuo, Thompson, Alexis, Swinford, Amy K., Dimitrov, Kiril M., Poulsen, Keith, and Kawaoka, Yoshihiro

Published
2024
Full Text
View/download PDF

4. A compendium of multi-omics data illuminating host responses to lethal human virus infections

Author

Eisfeld, Amie J., Anderson, Lindsey N., Fan, Shufang, Walters, Kevin B., Halfmann, Peter J., Westhoff Smith, Danielle, Thackray, Larissa B., Tan, Qing, Sims, Amy C., Menachery, Vineet D., Schäfer, Alexandra, Sheahan, Timothy P., Cockrell, Adam S., Stratton, Kelly G., Webb-Robertson, Bobbie-Jo M., Kyle, Jennifer E., Burnum-Johnson, Kristin E., Kim, Young-Mo, Nicora, Carrie D., Peralta, Zuleyma, N’jai, Alhaji U., Sahr, Foday, van Bakel, Harm, Diamond, Michael S., Baric, Ralph S., Metz, Thomas O., Smith, Richard D., Kawaoka, Yoshihiro, and Waters, Katrina M.

Published
2024
Full Text
View/download PDF

11. Safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65–85 years in the USA: a multicentre, randomised, double-blind, double-dummy, phase 1b trial

Author

Eiden, Joseph, Fierro, Carlos, White, Alexander, Davis, Matthew, Rhee, Margaret, Turner, Mark, Murray, Bryan, Herber, Renee, Aitchison, Roger, Marshall, David, Moser, Michael J, Belshe, Robert, Greenberg, Harry, Coelingh, Kathleen, Kawaoka, Yoshihiro, Neumann, Gabriele, and Bilsel, Pamuk

Published
2024
Full Text
View/download PDF

13. Host range, transmissibility and antigenicity of a pangolin coronavirus

Author

Hou, Yixuan J., Chiba, Shiho, Leist, Sarah R., Meganck, Rita M., Martinez, David R., Schäfer, Alexandra, Catanzaro, Nicholas J., Sontake, Vishwaraj, West, Ande, Edwards, Catlin E., Yount, Boyd, Lee, Rhianna E., Gallant, Samuel C., Zost, Seth J., Powers, John, Adams, Lily, Kong, Edgar F., Mattocks, Melissa, Tata, Aleksandra, Randell, Scott H., Tata, Purushothama R., Halfmann, Peter, Crowe, Jr, James E., Kawaoka, Yoshihiro, and Baric, Ralph S.

Published
2023
Full Text
View/download PDF

17. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates

Author

Uraki, Ryuta, Iida, Shun, Halfmann, Peter J., Yamayoshi, Seiya, Hirata, Yuichiro, Iwatsuki-Horimoto, Kiyoko, Kiso, Maki, Ito, Mutsumi, Furusawa, Yuri, Ueki, Hiroshi, Sakai-Tagawa, Yuko, Kuroda, Makoto, Maemura, Tadashi, Kim, Taksoo, Mine, Sohtaro, Iwamoto, Noriko, Li, Rong, Liu, Yanan, Larson, Deanna, Fukushi, Shuetsu, Watanabe, Shinji, Maeda, Ken, Wang, Zhongde, Ohmagari, Norio, Theiler, James, Fischer, Will, Korber, Bette, Imai, Masaki, Suzuki, Tadaki, and Kawaoka, Yoshihiro

Published
2023
Full Text
View/download PDF

18. Identification of SARS-CoV-2 Mpro inhibitors containing P1’ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2

Author

Higashi-Kuwata, Nobuyo, Tsuji, Kohei, Hayashi, Hironori, Bulut, Haydar, Kiso, Maki, Imai, Masaki, Ogata-Aoki, Hiromi, Ishii, Takahiro, Kobayakawa, Takuya, Nakano, Kenta, Takamune, Nobutoki, Kishimoto, Naoki, Hattori, Shin-ichiro, Das, Debananda, Uemura, Yukari, Shimizu, Yosuke, Aoki, Manabu, Hasegawa, Kazuya, Suzuki, Satoshi, Nishiyama, Akie, Saruwatari, Junji, Shimizu, Yukiko, Sukenaga, Yoshikazu, Takamatsu, Yuki, Tsuchiya, Kiyoto, Maeda, Kenji, Yoshimura, Kazuhisa, Iida, Shun, Ozono, Seiya, Suzuki, Tadaki, Okamura, Tadashi, Misumi, Shogo, Kawaoka, Yoshihiro, Tamamura, Hirokazu, and Mitsuya, Hiroaki

Published
2023
Full Text
View/download PDF

20. Defining the risk of SARS-CoV-2 variants on immune protection

Author

DeGrace, Marciela M, Ghedin, Elodie, Frieman, Matthew B, Krammer, Florian, Grifoni, Alba, Alisoltani, Arghavan, Alter, Galit, Amara, Rama R, Baric, Ralph S, Barouch, Dan H, Bloom, Jesse D, Bloyet, Louis-Marie, Bonenfant, Gaston, Boon, Adrianus CM, Boritz, Eli A, Bratt, Debbie L, Bricker, Traci L, Brown, Liliana, Buchser, William J, Carreño, Juan Manuel, Cohen-Lavi, Liel, Darling, Tamarand L, Davis-Gardner, Meredith E, Dearlove, Bethany L, Di, Han, Dittmann, Meike, Doria-Rose, Nicole A, Douek, Daniel C, Drosten, Christian, Edara, Venkata-Viswanadh, Ellebedy, Ali, Fabrizio, Thomas P, Ferrari, Guido, Fischer, Will M, Florence, William C, Fouchier, Ron AM, Franks, John, García-Sastre, Adolfo, Godzik, Adam, Gonzalez-Reiche, Ana Silvia, Gordon, Aubree, Haagmans, Bart L, Halfmann, Peter J, Ho, David D, Holbrook, Michael R, Huang, Yaoxing, James, Sarah L, Jaroszewski, Lukasz, Jeevan, Trushar, Johnson, Robert M, Jones, Terry C, Joshi, Astha, Kawaoka, Yoshihiro, Kercher, Lisa, Koopmans, Marion PG, Korber, Bette, Koren, Eilay, Koup, Richard A, LeGresley, Eric B, Lemieux, Jacob E, Liebeskind, Mariel J, Liu, Zhuoming, Livingston, Brandi, Logue, James P, Luo, Yang, McDermott, Adrian B, McElrath, Margaret J, Meliopoulos, Victoria A, Menachery, Vineet D, Montefiori, David C, Mühlemann, Barbara, Munster, Vincent J, Munt, Jenny E, Nair, Manoj S, Netzl, Antonia, Niewiadomska, Anna M, O’Dell, Sijy, Pekosz, Andrew, Perlman, Stanley, Pontelli, Marjorie C, Rockx, Barry, Rolland, Morgane, Rothlauf, Paul W, Sacharen, Sinai, Scheuermann, Richard H, Schmidt, Stephen D, Schotsaert, Michael, Schultz-Cherry, Stacey, Seder, Robert A, Sedova, Mayya, Sette, Alessandro, Shabman, Reed S, Shen, Xiaoying, Shi, Pei-Yong, Shukla, Maulik, Simon, Viviana, Stumpf, Spencer, Sullivan, Nancy J, Thackray, Larissa B, and Theiler, James

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Biological Sciences, Emerging Infectious Diseases, Pneumonia, Vaccine Related, Pneumonia & Influenza, Infectious Diseases, Biodefense, Immunization, Biotechnology, Prevention, Lung, Prevention of disease and conditions, and promotion of well-being, 2.1 Biological and endogenous factors, 3.4 Vaccines, Aetiology, Infection, Good Health and Well Being, Animals, Biological Evolution, COVID-19, COVID-19 Vaccines, Humans, National Institute of Allergy and Infectious Diseases (U.S.), Pandemics, Pharmacogenomic Variants, SARS-CoV-2, United States, Virulence, General Science & Technology
Abstract

The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or vaccination. To address the public health threat caused by the increasing SARS-CoV-2 genomic diversity, the National Institute of Allergy and Infectious Diseases within the National Institutes of Health established the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme. This effort was designed to provide a real-time risk assessment of SARS-CoV-2 variants that could potentially affect the transmission, virulence, and resistance to infection- and vaccine-induced immunity. The SAVE programme is a critical data-generating component of the US Government SARS-CoV-2 Interagency Group to assess implications of SARS-CoV-2 variants on diagnostics, vaccines and therapeutics, and for communicating public health risk. Here we describe the coordinated approach used to identify and curate data about emerging variants, their impact on immunity and effects on vaccine protection using animal models. We report the development of reagents, methodologies, models and notable findings facilitated by this collaborative approach and identify future challenges. This programme is a template for the response to rapidly evolving pathogens with pandemic potential by monitoring viral evolution in the human population to identify variants that could reduce the effectiveness of countermeasures.

Published
2022

21. Correlation Analysis between Gut Microbiota Alterations and the Cytokine Response in Patients with Coronavirus Disease during Hospitalization.

Author

Mizutani, Taketoshi, Ishizaka, Aya, Koga, Michiko, Ikeuchi, Kazuhiko, Saito, Makoto, Adachi, Eisuke, Yamayoshi, Seiya, Iwatsuki-Horimoto, Kiyoko, Yasuhara, Atsuhiro, Kiyono, Hiroshi, Matano, Tetsuro, Suzuki, Yutaka, Tsutsumi, Takeya, Kawaoka, Yoshihiro, and Yotsuyanagi, Hiroshi

Subjects
COVID-19 pathogenesis, gut microbiota, immune response, inflammation, microbiome, Bacteria, COVID-19, Cytokines, Dysbiosis, Feces, Gastrointestinal Microbiome, Hospitalization, Humans, Inflammation, RNA, Ribosomal, 16S
Abstract

The role of the intestinal microbiota in coronavirus disease 2019 (COVID-19) is being elucidated. Here, we analyzed the temporal changes in microbiota composition and the correlation between inflammation biomarkers/cytokines and microbiota in hospitalized COVID-19 patients. We obtained stool specimens, blood samples, and patient records from 22 hospitalized COVID-19 patients and performed 16S rRNA metagenomic analysis of stool samples over the course of disease onset compared to 40 healthy individual stool samples. We analyzed the correlation between the changes in the gut microbiota and plasma proinflammatory cytokine levels. Immediately after admission, differences in the gut microbiota were observed between COVID-19 patients and healthy subjects, mainly including enrichment of the classes Bacilli and Coriobacteriia and decrease in abundance of the class Clostridia. The bacterial profile continued to change throughout the hospitalization, with a decrease in short-chain fatty acid-producing bacteria including Faecalibacterium and an increase in the facultatively anaerobic bacteria Escherichia-Shigella. A consistent increase in Eggerthella belonging to the class Coriobacteriia was observed. The abundance of the class Clostridia was inversely correlated with interferon-γ level and that of the phylum Actinobacteria, which was enriched in COVID-19, and was positively correlated with gp130/sIL-6Rb levels. Dysbiosis was continued even after 21 days from onset. The intestines tended to be an aerobic environment in hospitalized COVID-19 patients. Because the composition of the gut microbiota correlates with the levels of proinflammatory cytokines, this finding emphasizes the need to understand how pathology is related to the temporal changes in the specific gut microbiota observed in COVID-19 patients. IMPORTANCE There is growing evidence that the commensal microbiota of the gastrointestinal and respiratory tracts regulates local and systemic inflammation (gut-lung axis). COVID-19 is primarily a respiratory disease, but the involvement of microbiota changes in the pathogenesis of this disease remains unclear. The composition of the gut microbiota of patients with COVID-19 changed over time during hospitalization, and the intestines tended to be an aerobic environment in hospitalized COVID-19 patients. These changes in gut microbiota may induce increased intestinal permeability, called leaky gut, allowing bacteria and toxins to enter the circulatory system and further aggravate the systemic inflammatory response. Since gut microbiota composition correlates with levels of proinflammatory cytokines, this finding highlights the need to understand how pathology relates to the gut environment, including the temporal changes in specific gut microbiota observed in COVID-19 patients.

Published
2022

24. Tracing the origin of SARS-CoV-2 omicron-like spike sequences detected in an urban sewershed: a targeted, longitudinal surveillance study of a cryptic wastewater lineage

Author

Shafer, Martin M, Bobholz, Max J, Vuyk, William C, Gregory, Devon A, Roguet, Adelaide, Haddock Soto, Luis A, Rushford, Clayton, Janssen, Kayley H, Emmen, Isla E, Ries, Hunter J, Pilch, Hannah E, Mullen, Paige A, Fahney, Rebecca B, Wei, Wanting, Lambert, Matthew, Wenzel, Jeff, Halfmann, Peter, Kawaoka, Yoshihiro, Wilson, Nancy A, Friedrich, Thomas C, Pray, Ian W, Westergaard, Ryan, O’Connor, David H, and Johnson, Marc C

Published
2024
Full Text
View/download PDF

27. Hypergraph Models of Biological Networks to Identify Genes Critical to Pathogenic Viral Response

Author

Feng, Song, Heath, Emily, Jefferson, Brett, Joslyn, Cliff, Kvinge, Henry, Mitchell, Hugh D., Praggastis, Brenda, Eisfeld, Amie J., Sims, Amy C., Thackray, Larissa B., Fan, Shufang, Walters, Kevin B., Halfmann, Peter J., Westhoff-Smith, Danielle, Tan, Qing, Menachery, Vineet D., Sheahan, Timothy P., Cockrell, Adam S., Kocher, Jacob F., Stratton, Kelly G., Heller, Natalie C., Bramer, Lisa M., Diamond, Michael S., Baric, Ralph S., Waters, Katrina M., Kawaoka, Yoshihiro, McDermott, Jason E., and Purvine, Emilie

Subjects
Quantitative Biology - Quantitative Methods, Mathematics - Combinatorics, 92C42, 92-08, 05C65
Abstract

Background: Representing biological networks as graphs is a powerful approach to reveal underlying patterns, signatures, and critical components from high-throughput biomolecular data. However, graphs do not natively capture the multi-way relationships present among genes and proteins in biological systems. Hypergraphs are generalizations of graphs that naturally model multi-way relationships and have shown promise in modeling systems such as protein complexes and metabolic reactions. In this paper we seek to understand how hypergraphs can more faithfully identify, and potentially predict, important genes based on complex relationships inferred from genomic expression data sets. Results: We compiled a novel data set of transcriptional host response to pathogenic viral infections and formulated relationships between genes as a hypergraph where hyperedges represent significantly perturbed genes, and vertices represent individual biological samples with specific experimental conditions. We find that hypergraph betweenness centrality is a superior method for identification of genes important to viral response when compared with graph centrality. Conclusions: Our results demonstrate the utility of using hypergraphs to represent complex biological systems and highlight central important responses in common to a variety of highly pathogenic viruses.

Published
2020

30. Isolation of Bat Sarbecoviruses, Japan

Author

Murakami, Shin, Kitamura, Tomoya, Matsugo, Hiromichi, Kamiki, Haruhiko, Oyabu, Ken, Sekine, Wataru, Takenaka-Uema, Akiko, Sakai-Tagawa, Yuko, Kawaoka, Yoshihiro, and Horimoto, Taisuke

Subjects
Bats -- Health aspects, Coronaviruses -- Identification and classification -- Distribution -- Genetic aspects, Company distribution practices, Health
Abstract

Human betacoronaviruses are divided into 2 pathotypes: endemic viruses, such as human coronavirus OC43 (HCoV-OC43) and HCoV-HKUl, which cause mild respiratory symptoms (1), and highly pathogenic viruses comprising severe acute [...]

Published
2022
Full Text
View/download PDF

31. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents

Author

Uraki, Ryuta, Halfmann, Peter J., Iida, Shun, Yamayoshi, Seiya, Furusawa, Yuri, Kiso, Maki, Ito, Mutsumi, Iwatsuki-Horimoto, Kiyoko, Mine, Sohtaro, Kuroda, Makoto, Maemura, Tadashi, Sakai-Tagawa, Yuko, Ueki, Hiroshi, Li, Rong, Liu, Yanan, Larson, Deanna, Fukushi, Shuetsu, Watanabe, Shinji, Maeda, Ken, Pekosz, Andrew, Kandeil, Ahmed, Webby, Richard J., Wang, Zhongde, Imai, Masaki, Suzuki, Tadaki, and Kawaoka, Yoshihiro

Published
2022
Full Text
View/download PDF

32. Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination

Author

Yamamoto, Shinya, Yamayoshi, Seiya, Ito, Mutsumi, Sakai-Tagawa, Yuko, Nakachi, Ichiro, Baba, Rie, Kamimoto, Shigenobu, Ogura, Takayuki, Hagiwara, Shigehiro, Kato, Hideaki, Nakajima, Hideaki, Uwamino, Yoshifumi, Yagi, Kazuma, Sugaya, Norio, Nagai, Hiroyuki, Saito, Makoto, Adachi, Eisuke, Koga, Michiko, Tsutsumi, Takeya, Duong, Calvin, Okuda, Moe, Murakami, Jurika, Furusawa, Yuri, Ujie, Michiko, Iwatsuki-Horimoto, Kiyoko, Yotsuyanagi, Hiroshi, and Kawaoka, Yoshihiro

Published
2023
Full Text
View/download PDF

34. Potent neutralizing broad-spectrum antibody against SARS-CoV-2 generated from dual-antigen-specific B cells from convalescents

Author

Takeshita, Masaru, Fukuyama, Hidehiro, Kamada, Katsuhiko, Matsumoto, Takehisa, Makino-Okamura, Chieko, Lin, Qingshun, Sakuma, Machie, Kawahara, Eiki, Yamazaki, Isato, Uchikubo-Kamo, Tomomi, Tomabechi, Yuri, Hanada, Kazuharu, Hisano, Tamao, Moriyama, Saya, Takahashi, Yoshimasa, Ito, Mutsumi, Imai, Masaki, Maemura, Tadashi, Furusawa, Yuri, Yamayoshi, Seiya, Kawaoka, Yoshihiro, Shirouzu, Mikako, Ishii, Makoto, Saya, Hideyuki, Kondo, Yasushi, Kaneko, Yuko, Suzuki, Katsuya, Fukunaga, Koichi, and Takeuchi, Tsutomu

Published
2023
Full Text
View/download PDF

35. Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020-March 2022

Author

Yamayoshi, Seiya, Iwatsuki-Horimoto, Kiyoko, Okuda, Moe, Ujie, Michiko, Yasuhara, Atsuhiro, Murakami, Jurika, Duong, Calvin, Hamabata, Taiki, Ito, Mutsumi, Chiba, Shiho, Kobayashi, Ryo, Takahashi, Satoshi, Mitamura, Keiko, Hagihara, Masao, Shibata, Akimichi, Uwamino, Yoshifumi, Hasegawa, Naoki, Ebina, Toshiaki, Izumi, Akihiko, Kato, Hideaki, Nakajima, Hideaki, Sugaya, Norio, Seki, Yuki, Iqbal, Asef, Kamimaki, Isamu, Yamazaki, Masahiko, Kawaoka, Yoshihiro, and Furuse, Yuki

Subjects
Age factors in disease -- Analysis, Prevalence studies (Epidemiology) -- Methods, Health
Abstract

SARS-CoV-2, the etiologic agent of COVID-19, emerged at the end of 2019 and caused a pandemic. As of April 2022, despite the development of effective vaccines and therapeutics, >500 million [...]

Published
2022
Full Text
View/download PDF

37. High titers of infectious SARS-CoV-2 in corpses of patients with COVID-19

Author

Saitoh, Hisako, Sakai-Tagawa, Yuko, Nagasawa, Sayaka, Torimitsu, Suguru, Kubota, Kazumi, Hirata, Yuichiro, Iwatsuki-Horimoto, Kiyoko, Motomura, Ayumi, Ishii, Namiko, Okaba, Keisuke, Horioka, Kie, Abe, Hiroyuki, Ikemura, Masako, Rokutan, Hirofumi, Hinata, Munetoshi, Iwasaki, Akiko, Yasunaga, Yoichi, Nakajima, Makoto, Yamaguchi, Rutsuko, Tsuneya, Shigeki, Kira, Kei, Kobayashi, Susumu, Inokuchi, Go, Chiba, Fumiko, Hoshioka, Yumi, Mori, Aika, Yamamoto, Isao, Nakagawa, Kimiko, Katano, Harutaka, Iida, Shun, Suzuki, Tadaki, Akitomi, Shinji, Hasegawa, Iwao, Ushiku, Tetsuo, Yajima, Daisuke, Iwase, Hirotaro, Makino, Yohsuke, and Kawaoka, Yoshihiro

Published
2023
Full Text
View/download PDF

38. Multi-omics of NET formation and correlations with CNDP1, PSPB, and L-cystine levels in severe and mild COVID-19 infections

Author

Bramer, Lisa M., Hontz, Robert D., Eisfeld, Amie J., Sims, Amy C., Kim, Young-Mo, Stratton, Kelly G., Nicora, Carrie D., Gritsenko, Marina A., Schepmoes, Athena A., Akasaka, Osamu, Koga, Michiko, Tsutsumi, Takeya, Nakamura, Morio, Nakachi, Ichiro, Baba, Rie, Tateno, Hiroki, Suzuki, Shoji, Nakajima, Hideaki, Kato, Hideaki, Ishida, Kazunari, Ishii, Makoto, Uwamino, Yoshifumi, Mitamura, Keiko, Paurus, Vanessa L., Nakayasu, Ernesto S., Attah, Isaac K., Letizia, Andrew G., Waters, Katrina M., Metz, Thomas O., Corson, Karen, Kawaoka, Yoshihiro, Gerbasi, Vincent R., Yotsuyanagi, Hiroshi, and Iwatsuki-Horimoto, Kiyoko

Published
2023
Full Text
View/download PDF

42. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2

Author

Uraki, Ryuta, Kiso, Maki, Iida, Shun, Imai, Masaki, Takashita, Emi, Kuroda, Makoto, Halfmann, Peter J., Loeber, Samantha, Maemura, Tadashi, Yamayoshi, Seiya, Fujisaki, Seiichiro, Wang, Zhongde, Ito, Mutsumi, Ujie, Michiko, Iwatsuki-Horimoto, Kiyoko, Furusawa, Yuri, Wright, Ryan, Chong, Zhenlu, Ozono, Seiya, Yasuhara, Atsuhiro, Ueki, Hiroshi, Sakai-Tagawa, Yuko, Li, Rong, Liu, Yanan, Larson, Deanna, Koga, Michiko, Tsutsumi, Takeya, Adachi, Eisuke, Saito, Makoto, Yamamoto, Shinya, Hagihara, Masao, Mitamura, Keiko, Sato, Tetsuro, Hojo, Masayuki, Hattori, Shin-ichiro, Maeda, Kenji, Valdez, Riccardo, Okuda, Moe, Murakami, Jurika, Duong, Calvin, Godbole, Sucheta, Douek, Daniel C., Maeda, Ken, Watanabe, Shinji, Gordon, Aubree, Ohmagari, Norio, Yotsuyanagi, Hiroshi, Diamond, Michael S., Hasegawa, Hideki, Mitsuya, Hiroaki, Suzuki, Tadaki, and Kawaoka, Yoshihiro

Published
2022
Full Text
View/download PDF

43. Characterization of a new SARS-CoV-2 variant that emerged in Brazil

Author

Imai, Masaki, Halfmann, Peter J., Yamayoshi, Seiya, Iwatsuki-Horimoto, Kiyoko, Chiba, Shiho, Watanabe, Tokiko, Nakajima, Noriko, Ito, Mutsumi, Kuroda, Makoto, Kiso, Maki, Maemura, Tadashi, Takahashi, Kenta, Loeber, Samantha, Hatta, Masato, Koga, Michiko, Nagai, Hiroyuki, Yamamoto, Shinya, Saito, Makoto, Adachi, Eisuke, Akasaka, Osamu, Nakamura, Morio, Nakachi, Ichiro, Ogura, Takayuki, Baba, Rie, Fujita, Kensuke, Ochi, Junichi, Mitamura, Keiko, Kato, Hideaki, Nakajima, Hideaki, Yagi, Kazuma, Hattori, Shin-ichiro, Maeda, Kenji, Suzuki, Tetsuya, Miyazato, Yusuke, Valdez, Riccardo, Gherasim, Carmen, Furusawa, Yuri, Okuda, Moe, Ujie, Michiko, Lopes, Tiago J. S., Yasuhara, Atsuhiro, Ueki, Hiroshi, Sakai-Tagawa, Yuko, Eisfeld, Amie J., Baczenas, John J., Baker, David A., O’Connor, Shelby L., O’Connor, David H., Fukushi, Shuetsu, Fujimoto, Tsuguto, Kuroda, Yudai, Gordon, Aubree, Maeda, Ken, Ohmagari, Norio, Sugaya, Norio, Yotsuyanagi, Hiroshi, Mitsuya, Hiroaki, Suzuki, Tadaki, and Kawaoka, Yoshihiro

Published
2021

44. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters

Author

Halfmann, Peter J., Iida, Shun, Iwatsuki-Horimoto, Kiyoko, Maemura, Tadashi, Kiso, Maki, Scheaffer, Suzanne M., Darling, Tamarand L., Joshi, Astha, Loeber, Samantha, Singh, Gagandeep, Foster, Stephanie L., Ying, Baoling, Case, James Brett, Chong, Zhenlu, Whitener, Bradley, Moliva, Juan, Floyd, Katharine, Ujie, Michiko, Nakajima, Noriko, Ito, Mutsumi, Wright, Ryan, Uraki, Ryuta, Warang, Prajakta, Gagne, Matthew, Li, Rong, Sakai-Tagawa, Yuko, Liu, Yanan, Larson, Deanna, Osorio, Jorge E., Hernandez-Ortiz, Juan P., Henry, Amy R., Ciuoderis, Karl, Florek, Kelsey R., Patel, Mit, Odle, Abby, Wong, Lok-Yin Roy, Bateman, Allen C., Wang, Zhongde, Edara, Venkata-Viswanadh, Chong, Zhenlu, Franks, John, Jeevan, Trushar, Fabrizio, Thomas, DeBeauchamp, Jennifer, Kercher, Lisa, Seiler, Patrick, Gonzalez-Reiche, Ana Silvia, Sordillo, Emilia Mia, Chang, Lauren A., van Bakel, Harm, Simon, Viviana, Douek, Daniel C., Sullivan, Nancy J., Thackray, Larissa B., Ueki, Hiroshi, Yamayoshi, Seiya, Imai, Masaki, Perlman, Stanley, Webby, Richard J., Seder, Robert A., Suthar, Mehul S., García-Sastre, Adolfo, Schotsaert, Michael, Suzuki, Tadaki, Boon, Adrianus C. M., Diamond, Michael S., and Kawaoka, Yoshihiro

Published
2022
Full Text
View/download PDF

48. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains

Author

Case, James Brett, Mackin, Samantha, Errico, John M., Chong, Zhenlu, Madden, Emily A., Whitener, Bradley, Guarino, Barbara, Schmid, Michael A., Rosenthal, Kim, Ren, Kuishu, Dang, Ha V., Snell, Gyorgy, Jung, Ana, Droit, Lindsay, Handley, Scott A., Halfmann, Peter J., Kawaoka, Yoshihiro, Crowe, Jr., James E., Fremont, Daved H., Virgin, Herbert W., Loo, Yueh-Ming, Esser, Mark T., Purcell, Lisa A., Corti, Davide, and Diamond, Michael S.

Published
2022
Full Text
View/download PDF

50. In vitro one-pot construction of influenza viral genomes for virus particle synthesis based on reverse genetics system.

Author

Tanaka, Ryota, Tamao, Kenji, Ono, Mana, Yamayoshi, Seiya, Kawaoka, Yoshihiro, Su'etsugu, Masayuki, Noji, Hiroyuki, and Tabata, Kazuhito V.

Subjects
VIRAL genomes, RECOMBINANT viruses, BASE pairs, VIRUS diseases, REPORTER genes, REVERSE genetics
Abstract

The reverse genetics system, which allows the generation of influenza viruses from plasmids encoding viral genome, is a powerful tool for basic research on viral infection mechanisms and application research such as vaccine development. However, conventional plasmid construction using Escherichia coli (E.coli) cloning is time‐consuming and has difficulties handling DNA encoding genes toxic for E.coli or highly repeated sequences. These limitations hamper rapid virus synthesis. In this study, we establish a very rapid in vitro one-pot plasmid construction (IVOC) based virus synthesis. This method dramatically reduced the time for genome plasmid construction, which was used for virus synthesis, from several days or more to about 8 hours. Moreover, infectious viruses could be synthesized with a similar yield to the conventional E.coli cloning-based method with high accuracy. The applicability of this method was also demonstrated by the generation of recombinant viruses carrying reporter genes from the IVOC products. This method enables the pathogenicity analysis and vaccine development using genetically modified viruses, and it is expected to allow for faster analysis of newly emerging variants than ever before. Furthermore, its application to other RNA viruses is also expected. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results